Jerjes Waseem, Theodossiou Theodossis A, Hirschberg Henry, Høgset Anders, Weyergang Anette, Selbo Pål Kristian, Hamdoon Zaid, Hopper Colin, Berg Kristian
UCL Medical School, London WC1E 6DE, UK.
North End Medical Centre, London W14 9PR, UK.
J Clin Med. 2020 Feb 14;9(2):528. doi: 10.3390/jcm9020528.
Photochemical internalisation (PCI) is a unique intervention which involves the release of endocytosed macromolecules into the cytoplasmic matrix. PCI is based on the use of photosensitizers placed in endocytic vesicles that, following light activation, lead to rupture of the endocytic vesicles and the release of the macromolecules into the cytoplasmic matrix. This technology has been shown to improve the biological activity of a number of macromolecules that do not readily penetrate the plasma membrane, including type I ribosome-inactivating proteins (RIPs), gene-encoding plasmids, adenovirus and oligonucleotides and certain chemotherapeutics, such as bleomycin. This new intervention has also been found appealing for intracellular delivery of drugs incorporated into nanocarriers and for cancer vaccination. PCI is currently being evaluated in clinical trials. Data from the first-in-human phase I clinical trial as well as an update on the development of the PCI technology towards clinical practice is presented here.
光化学内化(PCI)是一种独特的干预方法,它涉及将内吞的大分子释放到细胞质基质中。PCI基于使用放置在内吞小泡中的光敏剂,在光激活后,导致内吞小泡破裂,并将大分子释放到细胞质基质中。这项技术已被证明能提高许多不易穿透质膜的大分子的生物活性,包括I型核糖体失活蛋白(RIPs)、基因编码质粒、腺病毒、寡核苷酸以及某些化疗药物,如博来霉素。这种新的干预方法还被发现对于纳米载体中所含药物的细胞内递送以及癌症疫苗接种很有吸引力。目前正在对PCI进行临床试验评估。本文介绍了首次人体I期临床试验的数据以及PCI技术向临床应用发展的最新情况。